The initial success of Sildenafil undeniably transformed the drug landscape, but betting in companies heavily reliant on off-patent versions presents a complex picture. While early earnings were impressive, the cessation of patents and the rise of less expensive alternatives have diminished sales. Consequently, a thorough assessment of current inco